[ad_1]
Wall Street brokers predict Crispr Therapeutics AG (NASDAQ: CRSP) to report earnings per share of $ 0.65 for the quarter Zacks Investment Research Three badysts provided estimates for the benefit of Crispr Therapeutics, with earnings per share estimate being the highest ($ 0.60) and the lowest estimate setting it at ($ 0.71). The company is expected to release its next earnings report on Thursday, August 9th.
On average, badysts expect Crispr Therapeutics to report Earnings per share amount to $ (2.60) per share for the current year, estimates of EPS ranging from ($ 2.89) to ($ 2.38) for the next fiscal year, badysts predict that net earnings will be $ 2.74 per share. rangin g estimates of ($ 3.46) to ($ 1.90). The Zacks EPS calculations are a mean average based on a survey of research firms that cover Crispr Therapeutics.
Crispr Therapeutics (NASDAQ: CRSP) last published its financial results on Wednesday, May 9th. The company reported earnings per share of $ 0.62 for the quarter, up $ 0.05 from consensus estimates from Zacks ($ 0.67). The company achieved a turnover of $ 1.36 million during the quarter, against $ 3.64 million for badysts. Crispr Therapeutics recorded a negative net margin of 189.60% and a negative return on equity of 35.18%. The quarterly business turnover of the company is down 49.6% over the same quarter of last year. During the same period last year, the company earned ($ 0.54) earnings per share.
A number of equity research badysts have recently commented on CRSP actions. Piper Jaffray Companies reiterated an "overweight" rating and issued a target price of $ 53.70 ($ 67.00) on Crispr Therapeutics shares in a research report on Friday, March 9. Goldman Sachs Group began to hedge Crispr Therapeutics shares in a research report on Friday, April 6th. They issued a note "buy" and a target price of $ 86.00 for the company. Zacks Investment Research upgraded Crispr Therapeutics' shares from "hold" to "buy" and set a target price of $ 71.00 for the company in a research report on Wednesday, May 23. ValuEngine updated the Crispr Therapeutics shares from a "sale" rating to a "conservation" note in a research report on Monday, April 2nd. Finally, BidaskClub has downgraded Crispr Therapeutics shares from a "strong buy" rating to a "buy" note in a research report on Tuesday, June 5th. Three research badysts rated the stock with a conservation rating and nine issued a buy-to-action rating. The company has a consensual rating of "Buy" and a consensus price target of $ 65.90
In other news from Crispr Therapeutics, Bradley J. Phd Bolzon sold 101,994 shares in a transaction dated Monday, April 23. The shares were sold at an average price of $ 50.68, for a total transaction of $ 5,169,055.92. Following the completion of the transaction, the director now holds 43,986 shares of the Company, valued at $ 2,229,210.48. The sale has been disclosed in a legal deposit with the SEC, which is available at this link. In addition, director Kurt Von Emster sold 650,000 shares in a transaction dated Monday, May 14. The stock was sold at an average price of $ 54.39, for a total transaction of $ 35,353,500.00. As a result of the transaction, the director now holds directly 5,629 shares of the company, valued at approximately $ 306,161.31. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,510,845 shares valued at $ 80,447,023. 37.70% of the stock is held by insiders of the company.
A number of hedge funds have recently changed their positions in the company. EAM Global Investors LLC purchased a new position in Crispr Therapeutics during the first quarter of approximately $ 1,089,000. CIBC World Markets Inc. Purchased a new position in Crispr Therapeutics during the first quarter, valued at approximately $ 1,156,000. Royal Bank of Canada increased its interest in Crispr Therapeutics by 91.9% in the first quarter. Royal Bank of Canada now holds 26,620 shares of the company valued at $ 1,217,000 after purchasing an additional 12,751 shares during the period. Hilltop Holdings Inc. has purchased a new position in Crispr Therapeutics shares in the first quarter valued at approximately $ 919,000. Finally, LPL Financial LLC bought a new position in Crispr Therapeutics shares in the first quarter valued at about $ 256,000. 39.66% of the shares are held by institutional investors.
Crispr Therapeutics shares opened Monday at $ 62.88, according to MarketBeat Ratings. The stock has a market capitalization of $ 2.91 billion, a capitalization ratio of -36.77 and a beta of 4.19. Crispr Therapeutics has a 52-week low of $ 15.67 and a high of $ 52.90 in 52 weeks.
Crispr Therapeutics Company Presentation
CRISPR Therapeutics AG, Gene Publishing Company, focuses on the development of transformational gene-based drugs for the treatment of serious human diseases. 9 (CRISPR / Cas9) gene editing platform in Switzerland. Its main product candidate is CTX001, which targets sickle cell disease and beta-thalbademia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR / Cas9 therapeutic agent and reintroduced into the patient.
Get a Free Copy of the Zacks Research Report on Crispr Therapeutics (CRSP)
For more information on Zacks Investment Research's research offerings, visit Zacks.com
Receive news and ratings for Crispr Therapeutics Daily – Enter your email address below to receive a concise summary of the latest news and badyst ratings for Crispr Therapeutics and related companies with MarketBeat.com's free daily e-newsletter.
Source link
